Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Global HIV/AIDS Bill Clears Senate; Kennedy Pricing Amendment Fails

  • News

Executive Summary

The Bush Administration's global HIV/AIDS initiative is on a fast track to becoming law following Senate passage of HR 1298

You may also be interested in...



IoM AIDS Report Urges International Treatment Quality Assurance Standard

The Institute of Medicine recommends the creation of international quality assurance systems to ensure the quality of AIDS treatments for the developing world

IoM AIDS Report Urges International Treatment Quality Assurance Standard

The Institute of Medicine recommends the creation of international quality assurance systems to ensure the quality of AIDS treatments for the developing world

Lilly White House Connections On Display; Tobias To Oversee AIDS Fund

Former Lilly CEO Randall Tobias will oversee the Bush Administration's new fund to treat and prevent HIV in developing countries, President Bush announced July 2

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS041811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By